Astec LifeSciences Q1 FY27: posts net loss of ₹18.72 crore, revenue down 8%

What happened

In a filing with the BSE on 26 October 2026 at 05:12 PM, Astec LifeSciences (ASTEC) said that it has published its Q1 FY27 results (consolidated), reporting revenue of ₹83.56 crore (−8.3% year on year), a net loss of ₹18.72 crore (+43.3%), earnings per share of ₹-8.4.

Company snapshot

Astec LifeSciences is a small-cap company, with a market value of about ₹1,479 crore.

The stock last traded at ₹663.7, against a 52-week range of ₹513.4–₹941.8 (29.5% below the high).

Before this filing the shares had moved −12.4% over the month and −0.1% over three months. Average daily turnover over the last 20 sessions was about ₹8 crore.

Promoters held 71.96% at the end of Q1 FY27, down 0.01% points from the previous quarter. Foreign institutions owned 0.01% and domestic institutions 3.33%.

What history shows

This is not the company's first results disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.

Market-wide, 9,745 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• Management commentary, margins and order book or guidance in the investor presentation.
• 26 October 2026: Board meeting — Financial Results.

In the news

Recent coverage elsewhere (links open the original publisher):

• Astec Lifesciences Share Price — Upstox, 23 Oct 2026
• Astec Lifesciences Limited Estimates – NSE:ASTEC — TradingView, 25 Oct 2026
• Astec LifeSciences reports substantial loss for quarter ended September 2026 — Business Upturn, 26 Oct 2026

Source

• Exchange filing (PDF)